AUROBINDO PHARMA LTD.
NSE : AUROPHARMABSE : 524804ISIN
CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse
: Aurobindo
BSE1151.8020.65 (+1.83 % )
PREV CLOSE (Rs.) 1131.15
OPEN PRICE (Rs.) 1135.65
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 45247
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE1151.80 20.5 (+1.81 % )
PREV CLOSE(Rs.) 1131.30
OPEN PRICE (Rs.) 1137.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 1151.80 (142 )
VOLUME 2471250
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 22-Apr-2024 | Aurobindo Pharma informs about details of loss of certificate | <div style="text-align: justify;">Aurobindo Pharma has informed that the Company has received the letters from the following shareholder informing about the loss of share certificate and requested for issue of duplicate share certificate: B P Jalajakshi (Folio No. APL029127). KFin Technologies, Registrar and Share Transfer Agents of the Company has recorded the stop transfer against the aforesaid shares and they are processing his request for issue of duplicate share certificate.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 08-Apr-2024 | Aurobindo Pharma informs about issuance of letter(s) of confirmation | <p style="text-align: justify;">Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of SEBI Circular No. SEBI / HO / MIRSD / MIRSD_RTAMB / P / CIR / 2022 / 8 dated January 25, 2022, Aurobindo Pharma has informed that it enclosed the details of ‘Letter(s) of Confirmation' issued by the Company to its shareholder, in lieu of share certificate(s) reported as lost by him.</p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 05-Apr-2024 | USFDA concludes inspection at Andhra Pradesh facility of Aurobindo Pharma's arm | <p style="text-align: justify;">The United States Food and Drug Administration (USFDA) has concluded the inspection at Aurobindo Pharma's stepdown subsidiary -- Eugia Steriles' new injectable facility situated at Parawada Mandal, Anakapalli District, Andhra Pradesh. </p><p style="text-align: justify;">USFDA had conducted an inspection from March 28, 2024 to April 05, 2024. The inspection closed with 3 observations. The observations are procedural in nature and will be responded to within the stipulated time.</p><p style="text-align: justify;">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.</p> |
| 05-Apr-2024 | Aurobindo Pharma informs about disclosure with respect to non-applicability of large corporate | <p style="text-align: justify;">Aurobindo Pharma has confirmed that the Company is not falling under the category of 'Large Corporate' as per the applicability criteria mentioned under the aforesaid SEBI Circular.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div style="text-align: justify;"><br></div> |
| 03-Apr-2024 | Aurobindo Pharma informs about disclosure | <p style="text-align: justify;">Aurobindo Pharma has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Axis Trustee Services.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 20-Mar-2024 | Aurobindo Pharma gets final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray | <p style="text-align: justify;">Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray, 50 mcg/spray of Organon LLC. The product will be launched in Q1FY25.</p><p style="text-align: justify;">The approved product has an estimated market size of $44.5 million for the twelve months ending January 2024, according to IQVIA. Aurobindo now has a total of 507 ANDA approvals (488 Final approvals and 19 tentative approvals) from USFDA.</p><p style="text-align: justify;">Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and paediatric patients 2 years of age and older.</p><p style="text-align: justify;">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.</p> |
| 20-Mar-2024 | Aurobindo Pharma rises on getting final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray | <p style="text-align: justify;">Aurobindo Pharma is currently trading at Rs. 1004.05, up by 14.65 points or 1.48% from its previous closing of Rs. 989.40 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 1006.45 and has touched a high and low of Rs. 1013.90 and Rs. 996.00 respectively. So far 8516 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 466.00 on 21-Mar-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1022.35 and Rs. 985.05 respectively. The current market cap of the company is Rs. 57972.77 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.32% and 6.85% respectively.</p><p style="text-align: justify;">Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray, 50 mcg/spray of Organon LLC. The product will be launched in Q1FY25.</p><p style="text-align: justify;">The approved product has an estimated market size of $44.5 million for the twelve months ending January 2024, according to IQVIA. Aurobindo now has a total of 507 ANDA approvals (488 Final approvals and 19 tentative approvals) from USFDA.</p><p style="text-align: justify;">Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and paediatric patients 2 years of age and older.</p><p style="text-align: justify;">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.</p><div style="text-align: justify;"><br></div> |
| 13-Mar-2024 | Aurobindo Pharma's arm restarts distribution of aseptic products manufactured at Unit III | <p style="text-align: justify;">Aurobindo Pharma's wholly owned subsidiary-- Eugia Pharma Specialities has started distribution of aseptic products manufactured at Unit III, that was temporarily stopped. The company also expects to start commercial production from the aseptic lines of the said facility in a phased manner beginning next week and to re-start all the lines by April 15, 2024.</p><p style="text-align: justify;">Earlier, Eugia Pharma Specialities had restarted production in its terminally sterilized product lines at its Unit-III. The production was temporarily stopped to address some of the observations of United States Food and Drug Administration (USFDA) in their recent inspection concluded on February 2, 2024. </p><p style="text-align: justify;">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.</p><div style="text-align: justify;"><br></div> |
| 06-Mar-2024 | Aurobindo Pharma informs about media meet | <p style="text-align: justify;">Aurobindo Pharma has informed that the officials of the Company will be participating in the Media group meeting arranged by Ad factors on March 13, 202 at 4 03:45 am to 04:45 pm (IST) in Hyderabad. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 04-Mar-2024 | Aurobindo Pharma rises on getting final nod to manufacture, market Fingolimod Capsules, 0.5 mg | <p style="text-align: justify;">Aurobindo Pharma is currently trading at Rs. 1097.35, up by 21.25 points or 1.97% from its previous closing of Rs. 1076.10 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 1077.50 and has touched a high and low of Rs. 1097.35 and Rs. 1072.00 respectively. So far 3359 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 443.15 on 14-Mar-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1097.35 and Rs. 1012.00 respectively. The current market cap of the company is Rs. 63052.85 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.32% and 6.85% respectively.</p><p style="text-align: justify;">Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fingolimod Capsules, 0.5 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation. The product will be launched in March 2024.</p><p style="text-align: justify;">The approved product has an estimated market size of $447.3 million for the twelve months ending January 2024, according to IQVIA. Aurobindo now has a total of 505 ANDA approvals (486 Final approvals and 19 tentative approvals) from USFDA.</p><p style="text-align: justify;">Fingolimod Capsules, 0.5 mg, is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. </p><p style="text-align: justify;">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.</p><div style="text-align: justify;"><br></div> |
